STAT3 and lung carcinoma: In addition, STAT3 partially coordinates the cisplatin-resistance phenotype in non–small-cell lung cancer, providing support for the combination of cisplatin, rapamycin, and STAT3 abrogation as a rational therapeutic approach for lung cancer (57).